| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 07/03/2013 | CN103182092A Bone generation by gene therapy |
| 07/03/2013 | CN103182091A Polypeptide-modified drug delivery system targeting influenza virus-infected cells and preparation method and use thereof |
| 07/03/2013 | CN103182090A Dna疫苗 Dna Vaccine |
| 07/03/2013 | CN103182089A Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene |
| 07/03/2013 | CN103182088A PLGA modified magnetic nanocluster and preparation method and application thereof |
| 07/03/2013 | CN103182087A Trimethyl chitosan-graft-polyethylene glycol/nucleic acid brain-targeting micellar and preparation method thereof |
| 07/03/2013 | CN102641509B Application of Epstein barr (EB) virus miR-BART7 antisense oligonucleotide in preparing medicine capable of treating nasopharynx cancer |
| 07/03/2013 | CN102517283B Special short hairpin ribonucleic acid (shRNA) for reducing human IQGAP1 gene expression and application thereof |
| 07/03/2013 | CN101712949B gM-negative EHV-mutants without heterologous elements |
| 07/02/2013 | US8476245 Inhibition of tumor growth and invasion by anti matrix metalloproteinase DNAzymes |
| 07/02/2013 | US8476243 Methods and compositions for treating keratin hyperproliferative disorders |
| 07/02/2013 | CA2568898C Viral vectors controlled by a gene switch |
| 07/02/2013 | CA2562904C Cancer treatment using viruses and camptothecins |
| 07/02/2013 | CA2512144C Solid surface for biomolecule delivery and high-throughput assay |
| 07/02/2013 | CA2504582C Drug delivery device comprising a bilayered polymeric coating having an inhibitor of the mamalian target of rapamycin incorporated into the first polymeric coating layer |
| 07/02/2013 | CA2478508C Stable adenoviral vectors and methods for propagation thereof |
| 07/02/2013 | CA2421151C Modified vaccinia ankara virus variant |
| 07/02/2013 | CA2401974C Dna expression vectors and methods of use |
| 06/27/2013 | WO2013096806A1 Immune stimulation/metabolic inhibition as antitumor therapy |
| 06/27/2013 | WO2013091293A1 Medicine which relates to human gene nlk and use thereof |
| 06/27/2013 | WO2013091130A1 Porcine cd28 receptor, gene for coding same and application of same |
| 06/27/2013 | WO2013033705A3 Non-natural nucleosides as theranostic agents |
| 06/27/2013 | US20130165634 Expression and export of angiogenesis inhibitors as immunofusins |
| 06/27/2013 | US20130165503 Method for Treating Ocular Neovascularization |
| 06/27/2013 | US20130165502 Diagnostic, Prognostic and Therapeutic Uses of miRs in Adaptive Pathways and Disease Pathways |
| 06/27/2013 | US20130164843 Method and medicament for inhibiting the expression of a given gene |
| 06/27/2013 | US20130164721 Augmented cognitive training |
| 06/27/2013 | US20130164366 Method and medicament for inhibiting the expression of a given gene |
| 06/27/2013 | US20130164262 Recombinant Viruses and their Use for Treatment of Atherosclerosis and Othe Forms of Coronary Artery Disease and Method, Reagent, and Kit for Evaluating Susceptibiity to Same |
| 06/26/2013 | EP2606910A1 Pharmaceutical composition for transcolonic absorption |
| 06/26/2013 | EP2606901A1 Neuregulin based methods and compositions for treating cardiovascular diseases |
| 06/26/2013 | EP2606152A2 Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd) |
| 06/26/2013 | EP2606137A2 Anti-cancer adenoviruses |
| 06/26/2013 | EP2606132A1 C6orf167 as a target gene for cancer therapy and diagnosis |
| 06/26/2013 | EP2605799A2 Conjugates, particles, compositions, and related methods |
| 06/26/2013 | EP2605798A1 Gene therapy composition for use in diabetes treatment |
| 06/26/2013 | EP2605755A1 Particulate substances comprising ceramic particles for delivery of biomolecules |
| 06/26/2013 | CN103180448A Anti-cancer adenoviruses |
| 06/26/2013 | CN103180446A Vesicular stomatitis viruses |
| 06/26/2013 | CN103180445A Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
| 06/26/2013 | CN103180441A Skin and hair color-controlling factor |
| 06/26/2013 | CN103179989A Small liposomes for delivery of immunogen-encoding rna |
| 06/26/2013 | CN103179988A Pharmaceutical composition for transcolonic absorption |
| 06/26/2013 | CN103179982A Protein fusion constructs possessing thrombolytic and anticoagulant properties |
| 06/26/2013 | CN103173529A Associated use of human NLK (Neuroleukin) gene and associated medicines |
| 06/26/2013 | CN103173522A Micromolecule nucleic acid miR-383 and diagnosis and treatment application thereof |
| 06/26/2013 | CN103173494A Preparation containing recombinant adenovirus |
| 06/26/2013 | CN103173493A Preparation containing recombinant adenovirus |
| 06/26/2013 | CN103173480A Method for screening multidrug resistance related microRNA (ribonucleic acid) by using dual-luciferase report genes |
| 06/26/2013 | CN103173455A Goose-origin gene RIG-I (retinoic acid-inducible gene-I) with anti-Newcastle disease virus activities and application thereof |
| 06/26/2013 | CN103173451A Myocardial specific promoter |
| 06/26/2013 | CN103173447A Novel beta-actin and rps21 promoters and uses thereof |
| 06/26/2013 | CN103173446A Construction method of recombinant adeno-associated virus vector of targeting interference SOCS1 gene and application of construction method |
| 06/26/2013 | CN103172753A Fusion protein of GFE-1 and rmhTNF (recombinant mutant human Tumor Necrosis Factor) alpha and preparation method thereof |
| 06/26/2013 | CN103172751A Fusion protein of PA4-Fc and coding gene and application thereof |
| 06/26/2013 | CN103169987A Medicine for controlling melanin synthesis and improving skin whitening |
| 06/26/2013 | CN103169986A Mosaic type DNA (Deoxyribonucleic Acid) vaccine pVAXI-Hsp 70/CD 80 for preventing and immunologically treating tuberculosis |
| 06/26/2013 | CN103169985A Choline analogue modified brain-targeting nano-delivery system and preparation method thereof |
| 06/26/2013 | CN102430129B Bone morphogenetic protein-2/basic fibroblast growth factor (BMP-2/bFGF) double-gene chitosan nano-microcapsules and application thereof |
| 06/26/2013 | CN102277384B PSA recombinant adeno-associated viral vector and its construction method and application |
| 06/26/2013 | CN102268457B Alpha-fetoprotein (AFP) recombinant adeno associated virus, and construction method and application thereof |
| 06/26/2013 | CN101605560B A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma |
| 06/26/2013 | CN101198358B Recombinant BCG strains with enhanced ability to escape the endosome |
| 06/25/2013 | US8471000 RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis |
| 06/25/2013 | US8470991 Immunocytokine sequences and uses thereof |
| 06/25/2013 | US8470990 Ribosome structure and protein synthesis inhibitors |
| 06/25/2013 | US8470891 Biodegradable block polymers for drug delivery, and methods related thereto |
| 06/25/2013 | US8470799 Compositions and methods for inhibiting expression of the HAMP gene |
| 06/25/2013 | US8470796 Treatment of cancer by inhibition of IGFBPs and clusterin |
| 06/25/2013 | US8470795 Antisense modulation of kinesin-like 1 expression |
| 06/25/2013 | US8470792 Compositions and methods for selective inhibition of VEGF |
| 06/25/2013 | US8470790 Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
| 06/25/2013 | US8470577 Viral vectors and their use in therapeutic methods |
| 06/25/2013 | US8470317 B7RP-1 antagonists |
| 06/25/2013 | US8470315 Non-natural ribonuclease conjugates as cytotoxic agents |
| 06/25/2013 | US8470312 Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
| 06/25/2013 | CA2653566C Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 06/25/2013 | CA2583147C Chimeric vectors |
| 06/25/2013 | CA2522894C Pharmaceutical composition comprising a bispecific antibody specific for epcam |
| 06/25/2013 | CA2513743C Reducing culling in herd animals growth hormone releasing hormone (ghrh) |
| 06/25/2013 | CA2446110C A system for inducible expression in eukaryotic cells |
| 06/25/2013 | CA2428744C Inhibition of lysozyme in treating sepsis-induced myocardial dysfunction |
| 06/25/2013 | CA2402718C Fish vaccine against piscirickettsia salmonis |
| 06/25/2013 | CA2313169C Engraftable neural progenitor and stem cells for brain tumor therapy |
| 06/25/2013 | CA2214453C Novel avian cytokines and genetic sequences encoding same |
| 06/20/2013 | WO2013090732A2 Collateral gene inactivation biomarkers and targets for cancer therapy |
| 06/20/2013 | WO2013090648A1 Modified nucleoside, nucleotide, and nucleic acid compositions |
| 06/20/2013 | WO2013090645A1 Methods for improving medical therapies |
| 06/20/2013 | WO2013090556A1 Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis |
| 06/20/2013 | WO2013090523A2 Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery |
| 06/20/2013 | WO2013090457A2 In vivo delivery of oligonucleotides |
| 06/20/2013 | WO2013090409A1 Large commercial scale lentiviral vector production system and vectors produced thereby |
| 06/20/2013 | WO2013090356A2 Opsin polypeptides and methods of use thereof |
| 06/20/2013 | WO2013090186A1 Modified nucleic acids, and acute care uses thereof |
| 06/20/2013 | WO2013089522A1 Novel oligonucleotide conjugates and use thereof |
| 06/20/2013 | WO2013089157A1 Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredient |
| 06/20/2013 | WO2013088446A1 Compositions and methods for modifying a predetermined target nucleic acid sequence |
| 06/20/2013 | WO2013055418A3 Cross-protective arenavirus vaccines and their method of use |
| 06/20/2013 | WO2013050529A3 Use of igf-1 in the stimulation of treg cell activity and the treatment autoimmune disorders |
| 06/20/2013 | US20130158502 Method of inhibiting angiogenesis or invasion or formation of metastases |